Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer.

novel systemic treatment options redefined the therapeutic algorithms for TNBC by establishing new paradigms, based on substantial clinical benefits. Pembrolizumab and Olaparib in the curative setting portend high-value, as shown with the use of value-frameworks, resulting in cost-effective interventions. In the metastatic setting, new drugs have demonstrated mixed improvements of patient-centric endpoints, resulting often in interventions unlikely to have good value for money. We believe that cost-effectiveness alone is not a metric to inform the opportunity to invest on new interventions, while the intrinsic value of medicines should be the driver of the decisions. We endorse a patient-centric priority-setting that can ensure health system sustainability, to timely deliver innovative cancer care to all in need and positively impact on population health.